Common Genetic Variation at BARD1 Is Not Associated with Breast Cancer Risk in BRCA1 or BRCA2 Mutation Carriers

Amanda B. Spurdle; Louise Marquart; Lesley McGuffog; Sue Healey; Olga M. Sinilnikova; Fei Wan; Xiaoqing Chen; Jonathan Beesley; Christian F. Singer; Anne-Catharine Dressler; Daphne Gschwantler-Kaulich; Joanne L. Blum; Nadine Tung; Jeff Weitzel; Henry T. Lynch; Judy Garber; Douglas F. Easton; Susan Peock; Margaret Cook; Clare T. Oliver; Debra Frost; Don Conroy; D. Gareth Evans; Fiona Lalloo; Ros Eeles; Louise Izatt; Rosemarie Davidson; Carol Chu; Diana Eccles; Christina G. Selkirk; Mary B. Daly; Claudine Isaacs; Dominique Stoppa-Lyonnet; Bruno Buecher; Muriel Belotti; Sylvie Mazoyer; Laure Barjhoux; Carole Verny-Pierre; Christine Lasset; Helene Dreyfus; Pascal Pujol; Marie-Agnes Collonge-Rame; Matti A. Rookus; Senno Verhoef; Mieke Kriege; Nicoline Hoogerbrugge; Margreet G. E. M. Ausems; Theo A. Mvan Os; Juul T. Wijnen; Peter Devilee; Hanne E. J. Meijers-Heijboer; Marinus J. Blok; Tuomas Heikkinen; Heli Nevanlinna; Anna Jakubowska; Jan Lubinski; Tomasz Huzarski; Tomasz Byrski; Francine Durocher; Fergus J. Couch; Noralane M. Lindor; Xianshu Wang; Mads Thomassen; Susan Domchek; Kate Nathanson; Maria A. Caligo; Helena Jernstrom; Annelie Liljegren; Hans Ehrencrona; Per Karlsson; Patricia A. Ganz; Olufunmilayo I. Olopade; Gail E. Tomlinson; Susan L. Neuhausen; Antonis C. Antoniou; Georgia Chenevix-Trench; Timothy R. Rebbeck

doi:10.1158/1055-9965.EPI-10-0909

Common Genetic Variation at BARD1 Is Not Associated with Breast Cancer Risk in BRCA1 or BRCA2 Mutation Carriers

Amanda B. Spurdle, Louise Marquart, Lesley McGuffog, Sue Healey, Olga M. Sinilnikova, Fei Wan, Xiaoqing Chen, Jonathan Beesley, Christian F. Singer, Anne-Catharine Dressler, Daphne Gschwantler-Kaulich, Joanne L. Blum, Nadine Tung, Jeff Weitzel, Henry T. Lynch, Judy Garber, Douglas F. Easton, Susan Peock, Margaret Cook, Clare T. OliverDebra Frost, Don Conroy, D. Gareth Evans, Fiona Lalloo, Ros Eeles, Louise Izatt, Rosemarie Davidson, Carol Chu, Diana Eccles, Christina G. Selkirk, Mary B. Daly, Claudine Isaacs, Dominique Stoppa-Lyonnet, Bruno Buecher, Muriel Belotti, Sylvie Mazoyer, Laure Barjhoux, Carole Verny-Pierre, Christine Lasset, Helene Dreyfus, Pascal Pujol, Marie-Agnes Collonge-Rame, Matti A. Rookus, Senno Verhoef, Mieke Kriege, Nicoline Hoogerbrugge, Margreet G. E. M. Ausems, Theo A. Mvan Os, Juul T. Wijnen, Peter Devilee, Hanne E. J. Meijers-Heijboer, Marinus J. Blok, Tuomas Heikkinen, Heli Nevanlinna, Anna Jakubowska, Jan Lubinski, Tomasz Huzarski, Tomasz Byrski, Francine Durocher, Fergus J. Couch, Noralane M. Lindor, Xianshu Wang, Mads Thomassen, Susan Domchek, Kate Nathanson, Maria A. Caligo, Helena Jernstrom, Annelie Liljegren, Hans Ehrencrona, Per Karlsson, Patricia A. Ganz, Olufunmilayo I. Olopade, Gail E. Tomlinson, Susan L. Neuhausen, Antonis C. Antoniou, Georgia Chenevix-Trench, Timothy R. Rebbeck^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background: Inherited BRCA1 and BRCA2 (BRCA1/2) mutations confer elevated breast cancer risk. Knowledge of factors that can improve breast cancer risk assessment in BRCA1/2 mutation carriers may improve personalized cancer prevention strategies. Methods: A cohort of 5,546 BRCA1 and 2,865 BRCA2 mutation carriers was used to evaluate risk of breast cancer associated with BARD1 Cys557Ser. In a second nonindependent cohort of 1,537 of BRCA1 and 839 BRCA2 mutation carriers, BARD1 haplotypes were also evaluated. Results: The BARD1 Cys557Ser variant was not significantly associated with risk of breast cancer from single SNP analysis, with a pooled effect estimate of 0.90 (95% CI: 0.71-1.15) in BRCA1 carriers and 0.87 (95% CI: 0.59-1.29) in BRCA2 carriers. Further analysis of haplotypes at BARD1 also revealed no evidence that additional common genetic variation not captured by Cys557Ser was associated with breast cancer risk. Conclusion: Evidence to date does not support a role for BARD1 variation, including the Cy557Ser variant, as a modifier of risk in BRCA1/2 mutation carriers. Impact: Interactors of BRCA1/2 have been implicated as modifiers of BRCA1/2-associated cancer risk. Our finding that BARD1 does not contribute to this risk modification may focus research on other genes that do modify BRCA1/2-associated cancer risk. Cancer Epidemiol Biomarkers Prev; 20(5); 1032-38.

Original language	English
Pages (from-to)	1032-1038
Journal	Cancer Epidemiology Biomarkers & Prevention
Volume	20
Issue number	5
DOIs	https://doi.org/10.1158/1055-9965.EPI-10-0909
Publication status	Published - May 2011

Access to Document

10.1158/1055-9965.EPI-10-0909

Cite this

Spurdle, A. B., Marquart, L., McGuffog, L., Healey, S., Sinilnikova, O. M., Wan, F., Chen, X., Beesley, J., Singer, C. F., Dressler, A.-C., Gschwantler-Kaulich, D., Blum, J. L., Tung, N., Weitzel, J., Lynch, H. T., Garber, J., Easton, D. F., Peock, S., Cook, M., ... Rebbeck, T. R. (2011). Common Genetic Variation at BARD1 Is Not Associated with Breast Cancer Risk in BRCA1 or BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers & Prevention, 20(5), 1032-1038. https://doi.org/10.1158/1055-9965.EPI-10-0909

@article{10fc35030be34aa893745530db3180ff,

title = "Common Genetic Variation at BARD1 Is Not Associated with Breast Cancer Risk in BRCA1 or BRCA2 Mutation Carriers",

abstract = "Background: Inherited BRCA1 and BRCA2 (BRCA1/2) mutations confer elevated breast cancer risk. Knowledge of factors that can improve breast cancer risk assessment in BRCA1/2 mutation carriers may improve personalized cancer prevention strategies. Methods: A cohort of 5,546 BRCA1 and 2,865 BRCA2 mutation carriers was used to evaluate risk of breast cancer associated with BARD1 Cys557Ser. In a second nonindependent cohort of 1,537 of BRCA1 and 839 BRCA2 mutation carriers, BARD1 haplotypes were also evaluated. Results: The BARD1 Cys557Ser variant was not significantly associated with risk of breast cancer from single SNP analysis, with a pooled effect estimate of 0.90 (95% CI: 0.71-1.15) in BRCA1 carriers and 0.87 (95% CI: 0.59-1.29) in BRCA2 carriers. Further analysis of haplotypes at BARD1 also revealed no evidence that additional common genetic variation not captured by Cys557Ser was associated with breast cancer risk. Conclusion: Evidence to date does not support a role for BARD1 variation, including the Cy557Ser variant, as a modifier of risk in BRCA1/2 mutation carriers. Impact: Interactors of BRCA1/2 have been implicated as modifiers of BRCA1/2-associated cancer risk. Our finding that BARD1 does not contribute to this risk modification may focus research on other genes that do modify BRCA1/2-associated cancer risk. Cancer Epidemiol Biomarkers Prev; 20(5); 1032-38. ",

author = "Spurdle, {Amanda B.} and Louise Marquart and Lesley McGuffog and Sue Healey and Sinilnikova, {Olga M.} and Fei Wan and Xiaoqing Chen and Jonathan Beesley and Singer, {Christian F.} and Anne-Catharine Dressler and Daphne Gschwantler-Kaulich and Blum, {Joanne L.} and Nadine Tung and Jeff Weitzel and Lynch, {Henry T.} and Judy Garber and Easton, {Douglas F.} and Susan Peock and Margaret Cook and Oliver, {Clare T.} and Debra Frost and Don Conroy and Evans, {D. Gareth} and Fiona Lalloo and Ros Eeles and Louise Izatt and Rosemarie Davidson and Carol Chu and Diana Eccles and Selkirk, {Christina G.} and Daly, {Mary B.} and Claudine Isaacs and Dominique Stoppa-Lyonnet and Bruno Buecher and Muriel Belotti and Sylvie Mazoyer and Laure Barjhoux and Carole Verny-Pierre and Christine Lasset and Helene Dreyfus and Pascal Pujol and Marie-Agnes Collonge-Rame and Rookus, {Matti A.} and Senno Verhoef and Mieke Kriege and Nicoline Hoogerbrugge and Ausems, {Margreet G. E. M.} and Os, {Theo A. Mvan} and Wijnen, {Juul T.} and Peter Devilee and Meijers-Heijboer, {Hanne E. J.} and Blok, {Marinus J.} and Tuomas Heikkinen and Heli Nevanlinna and Anna Jakubowska and Jan Lubinski and Tomasz Huzarski and Tomasz Byrski and Francine Durocher and Couch, {Fergus J.} and Lindor, {Noralane M.} and Xianshu Wang and Mads Thomassen and Susan Domchek and Kate Nathanson and Caligo, {Maria A.} and Helena Jernstrom and Annelie Liljegren and Hans Ehrencrona and Per Karlsson and Ganz, {Patricia A.} and Olopade, {Olufunmilayo I.} and Tomlinson, {Gail E.} and Neuhausen, {Susan L.} and Antoniou, {Antonis C.} and Georgia Chenevix-Trench and Rebbeck, {Timothy R.}",

year = "2011",

month = may,

doi = "10.1158/1055-9965.EPI-10-0909",

language = "English",

volume = "20",

pages = "1032--1038",

journal = "Cancer Epidemiology Biomarkers & Prevention",

issn = "1055-9965",

publisher = "American Association for Cancer Research Inc.",

number = "5",

}

Spurdle, AB, Marquart, L, McGuffog, L, Healey, S, Sinilnikova, OM, Wan, F, Chen, X, Beesley, J, Singer, CF, Dressler, A-C, Gschwantler-Kaulich, D, Blum, JL, Tung, N, Weitzel, J, Lynch, HT, Garber, J, Easton, DF, Peock, S, Cook, M, Oliver, CT, Frost, D, Conroy, D, Evans, DG, Lalloo, F, Eeles, R, Izatt, L, Davidson, R, Chu, C, Eccles, D, Selkirk, CG, Daly, MB, Isaacs, C, Stoppa-Lyonnet, D, Buecher, B, Belotti, M, Mazoyer, S, Barjhoux, L, Verny-Pierre, C, Lasset, C, Dreyfus, H, Pujol, P, Collonge-Rame, M-A, Rookus, MA, Verhoef, S, Kriege, M, Hoogerbrugge, N, Ausems, MGEM, Os, TAM, Wijnen, JT, Devilee, P, Meijers-Heijboer, HEJ, Blok, MJ, Heikkinen, T, Nevanlinna, H, Jakubowska, A, Lubinski, J, Huzarski, T, Byrski, T, Durocher, F, Couch, FJ, Lindor, NM, Wang, X, Thomassen, M, Domchek, S, Nathanson, K, Caligo, MA, Jernstrom, H, Liljegren, A, Ehrencrona, H, Karlsson, P, Ganz, PA, Olopade, OI, Tomlinson, GE, Neuhausen, SL, Antoniou, AC, Chenevix-Trench, G & Rebbeck, TR 2011, 'Common Genetic Variation at BARD1 Is Not Associated with Breast Cancer Risk in BRCA1 or BRCA2 Mutation Carriers', Cancer Epidemiology Biomarkers & Prevention, vol. 20, no. 5, pp. 1032-1038. https://doi.org/10.1158/1055-9965.EPI-10-0909

TY - JOUR

T1 - Common Genetic Variation at BARD1 Is Not Associated with Breast Cancer Risk in BRCA1 or BRCA2 Mutation Carriers

AU - Spurdle, Amanda B.

AU - Marquart, Louise

AU - McGuffog, Lesley

AU - Healey, Sue

AU - Sinilnikova, Olga M.

AU - Wan, Fei

AU - Chen, Xiaoqing

AU - Beesley, Jonathan

AU - Singer, Christian F.

AU - Dressler, Anne-Catharine

AU - Gschwantler-Kaulich, Daphne

AU - Blum, Joanne L.

AU - Tung, Nadine

AU - Weitzel, Jeff

AU - Lynch, Henry T.

AU - Garber, Judy

AU - Easton, Douglas F.

AU - Peock, Susan

AU - Cook, Margaret

AU - Oliver, Clare T.

AU - Frost, Debra

AU - Conroy, Don

AU - Evans, D. Gareth

AU - Lalloo, Fiona

AU - Eeles, Ros

AU - Izatt, Louise

AU - Davidson, Rosemarie

AU - Chu, Carol

AU - Eccles, Diana

AU - Selkirk, Christina G.

AU - Daly, Mary B.

AU - Isaacs, Claudine

AU - Stoppa-Lyonnet, Dominique

AU - Buecher, Bruno

AU - Belotti, Muriel

AU - Mazoyer, Sylvie

AU - Barjhoux, Laure

AU - Verny-Pierre, Carole

AU - Lasset, Christine

AU - Dreyfus, Helene

AU - Pujol, Pascal

AU - Collonge-Rame, Marie-Agnes

AU - Rookus, Matti A.

AU - Verhoef, Senno

AU - Kriege, Mieke

AU - Hoogerbrugge, Nicoline

AU - Ausems, Margreet G. E. M.

AU - Os, Theo A. Mvan

AU - Wijnen, Juul T.

AU - Devilee, Peter

AU - Meijers-Heijboer, Hanne E. J.

AU - Blok, Marinus J.

AU - Heikkinen, Tuomas

AU - Nevanlinna, Heli

AU - Jakubowska, Anna

AU - Lubinski, Jan

AU - Huzarski, Tomasz

AU - Byrski, Tomasz

AU - Durocher, Francine

AU - Couch, Fergus J.

AU - Lindor, Noralane M.

AU - Wang, Xianshu

AU - Thomassen, Mads

AU - Domchek, Susan

AU - Nathanson, Kate

AU - Caligo, Maria A.

AU - Jernstrom, Helena

AU - Liljegren, Annelie

AU - Ehrencrona, Hans

AU - Karlsson, Per

AU - Ganz, Patricia A.

AU - Olopade, Olufunmilayo I.

AU - Tomlinson, Gail E.

AU - Neuhausen, Susan L.

AU - Antoniou, Antonis C.

AU - Chenevix-Trench, Georgia

AU - Rebbeck, Timothy R.

PY - 2011/5

Y1 - 2011/5

N2 - Background: Inherited BRCA1 and BRCA2 (BRCA1/2) mutations confer elevated breast cancer risk. Knowledge of factors that can improve breast cancer risk assessment in BRCA1/2 mutation carriers may improve personalized cancer prevention strategies. Methods: A cohort of 5,546 BRCA1 and 2,865 BRCA2 mutation carriers was used to evaluate risk of breast cancer associated with BARD1 Cys557Ser. In a second nonindependent cohort of 1,537 of BRCA1 and 839 BRCA2 mutation carriers, BARD1 haplotypes were also evaluated. Results: The BARD1 Cys557Ser variant was not significantly associated with risk of breast cancer from single SNP analysis, with a pooled effect estimate of 0.90 (95% CI: 0.71-1.15) in BRCA1 carriers and 0.87 (95% CI: 0.59-1.29) in BRCA2 carriers. Further analysis of haplotypes at BARD1 also revealed no evidence that additional common genetic variation not captured by Cys557Ser was associated with breast cancer risk. Conclusion: Evidence to date does not support a role for BARD1 variation, including the Cy557Ser variant, as a modifier of risk in BRCA1/2 mutation carriers. Impact: Interactors of BRCA1/2 have been implicated as modifiers of BRCA1/2-associated cancer risk. Our finding that BARD1 does not contribute to this risk modification may focus research on other genes that do modify BRCA1/2-associated cancer risk. Cancer Epidemiol Biomarkers Prev; 20(5); 1032-38.

AB - Background: Inherited BRCA1 and BRCA2 (BRCA1/2) mutations confer elevated breast cancer risk. Knowledge of factors that can improve breast cancer risk assessment in BRCA1/2 mutation carriers may improve personalized cancer prevention strategies. Methods: A cohort of 5,546 BRCA1 and 2,865 BRCA2 mutation carriers was used to evaluate risk of breast cancer associated with BARD1 Cys557Ser. In a second nonindependent cohort of 1,537 of BRCA1 and 839 BRCA2 mutation carriers, BARD1 haplotypes were also evaluated. Results: The BARD1 Cys557Ser variant was not significantly associated with risk of breast cancer from single SNP analysis, with a pooled effect estimate of 0.90 (95% CI: 0.71-1.15) in BRCA1 carriers and 0.87 (95% CI: 0.59-1.29) in BRCA2 carriers. Further analysis of haplotypes at BARD1 also revealed no evidence that additional common genetic variation not captured by Cys557Ser was associated with breast cancer risk. Conclusion: Evidence to date does not support a role for BARD1 variation, including the Cy557Ser variant, as a modifier of risk in BRCA1/2 mutation carriers. Impact: Interactors of BRCA1/2 have been implicated as modifiers of BRCA1/2-associated cancer risk. Our finding that BARD1 does not contribute to this risk modification may focus research on other genes that do modify BRCA1/2-associated cancer risk. Cancer Epidemiol Biomarkers Prev; 20(5); 1032-38.

U2 - 10.1158/1055-9965.EPI-10-0909

DO - 10.1158/1055-9965.EPI-10-0909

M3 - Article

C2 - 21393566

SN - 1055-9965

VL - 20

SP - 1032

EP - 1038

JO - Cancer Epidemiology Biomarkers & Prevention

JF - Cancer Epidemiology Biomarkers & Prevention

IS - 5

ER -

Common Genetic Variation at BARD1 Is Not Associated with Breast Cancer Risk in BRCA1 or BRCA2 Mutation Carriers

Abstract

Access to Document

Fingerprint

Cite this